Comments on: The Uninvited: Sanjay Kaul removed from prasugrel’s FDA advisory panel

By: Oops, She Did It Again! FDA Disinvites Another Advisor « CardioBrief

Oops, She Did It Again! FDA Disinvites Another Advisor « CardioBrief — Thu, 08 Dec 2011 12:50:36 +0000

[...] was removed without explanation from the prasugrel (Efient, Lilly) advisory panel (as recounted here, here, here, and here), provoking considerable controversy and two congressional [...]

By: Chronology of Prasugrel Controversy « CardioBrief

Chronology of Prasugrel Controversy « CardioBrief — Mon, 23 Feb 2009 16:54:26 +0000

[...] http://cardiobrief.org/2009/02/02/sanjay-kaul-removed-from-prasugrels-fda-advisory-panel/ [...]

By: FDA provides “explanation” for Sanjay Kaul’s absence « CardioBrief

Wed, 11 Feb 2009 20:29:09 +0000

[...] Sanjay Kaul’s absence from the prasugrel advisory committee meeting (click to see our initial story that first reported his absence and our subsequent editorial about some serious questions raised by the advisory committee [...]

By: Editorial: prasugrel and FDA incompetence « CardioBrief

Editorial: prasugrel and FDA incompetence « CardioBrief — Mon, 09 Feb 2009 15:42:20 +0000

[...] first reported here previously, less than 48 hours before the advisory committee hearing new member Sanjay Kaul was [...]

By: Health Blog : Prasugrel Review Proceeds Without Key Safety Experts

Health Blog : Prasugrel Review Proceeds Without Key Safety Experts — Tue, 03 Feb 2009 17:34:17 +0000

[...] There’s another absence that’s also raising questions. Sanjay Kaul, a cardiologist at Cedars -Sinai Heart Institute and a voting member of the Cardio Advisory Committee, was removed from the panel last week over “intellectual conflict of interest,” according to the blog Cardio Brief. [...]